No abstract

Operant responding in rats provides an analog to voluntary behavior in humans and is used to study maladaptive behaviors, such as overeating, drug taking, or relapse. In renewal paradigms, extinguished behavior recovers when tested outside the context where extinction was learned. Inactivation of the prelimbic (PL) region of the medial prefrontal cortex by baclofen/muscimol (B/M) during testing attenuates renewal when tested in the original acquisition context after extinction in another context (ABA renewal). Two experiments tested the hypothesis that the PL is important in context-dependent responding learned during conditioning. In the first, rats learned to lever-press for a sucrose-pellet reward.

Several studies have examined a role for the prelimbic cortex (PL) and infralimbic cortex (IL) in free operant behavior. The general conclusion has been that PL controls goal-directed actions (instrumental behaviors that are sensitive to reinforcer devaluation) whereas IL controls habits (instrumental behaviors that are not sensitive to reinforcer devaluation). To further examine the involvement of these regions in the expression of instrumental behavior, we first implanted male rats with bilateral guide cannulae into their PL, then trained two responses to produce a sucrose pellet reinforcer, R1 and R2, each in a distinct context. R1 received extensive training and R2 received minimal training. Rats then received lithium chloride injections either paired or unpaired with sucrose pellets in both contexts until paired rats rejected all pellets. Following acquisition, in Experiment 1, rats received either an infusion of saline or baclofen/muscimol into the PL and were tested (in extinction) on both R1 and R2. In vehicle controls, both responses were goal-directed actions, as indicated by their sensitivity to reinforcer devaluation. PL inactivation decreased expression of the minimally-trained action without affecting expression of the extensively-trained action. Experiment 2 utilized the same experimental design but with IL inactivation at test. The extensively-trained response was again a goal-directed action. However, now expression of the extensively-trained goal-directed action was suppressed by IL inactivation. The overall pattern of results suggests that the PL is involved in expression of minimally trained goal-directed behavior while the IL is involved in expression of extensively trained goal-directed behavior. This implies that the PL does not control all types of actions and the IL can control some types of actions. These results expand upon the traditional view that the PL controls action while the IL controls habit.

Attention-Deficit/Hyperactivity Disorder (ADHD) is a common, chronic neurobehavioral disorder related to clinically significant levels of inattention, hyperactivity and/or impulsivity. ADHD begins in childhood and symptoms persist into adulthood for the majority of those with the disorder. Associated features of ADHD include emotion dysregulation and cognitive impairments which contribute to the considerable functional impairments in this disorder. Current approved treatments are reasonably effective however a significant need remains for new pharmacotherapies, both for individuals who do not achieve a full therapeutic response and for symptoms that are under-treated including cognition and emotion regulation. The striking relationship between ADHD and cigarette smoking and the known effects of nicotine on cognition has spurred research into the therapeutic potential of nicotinic agents for ADHD. Although there are no approved medications for ADHD that target nicotinic acetylcholine receptor (nAChR) function, results from many trials of nicotinic drugs are available and reviewed in this article. ADHD symptoms were reduced in the majority of published studies of nicotine and novel α4β2 nicotinic agonists in adult ADHD. The drugs were generally well tolerated, with mild to moderate side effects reported, which were largely consistent with cholinergic stimulation and included nausea, dizziness, and gastrointestinal distress. Within-subject crossover study designs were used in the majority of positive studies. This design may be particularly useful in ADHD trials because it minimizes variability in this notoriously heterogeneous diagnostic group. In addition, many studies found evidence for a beneficial effect of nicotinic stimulation on cognitive and emotional domains. Thus, targeting nAChRs in ADHD appears to have modest clinical benefit in adult ADHD. Continued refinement of nAChR agonists with greater specificity and fewer side effects may lead to even more effective nAChR agonists for ADHD. Future clinical trials in ADHD should include direct measures of neuropsychological performance and emotion regulation.

No abstract